Healthcare Times Guadeloupe
SEE OTHER BRANDS

Get your health and wellness news from Guadeloupe

Healthcare Times Guadeloupe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Guadeloupe.

Press releases published on July 21, 2025

CARBIOS steigt in den Markt für r-PET-Filamente für Reifenverstärkungsgewebe ein

CARBIOS steigt in den Markt für r-PET-Filamente für Reifenverstärkungsgewebe ein

CARBIOS hat eine mehrjährige kommerzielle Vereinbarung mit Indorama Ventures, dem weltweit führenden Hersteller von Polyester, unterzeichnet. CARBIOS wird in diesem Rahmen recycelte Monomere bereitstellen, die von Indorama Ventures zu Filamenten für die …

CARBIOS enters the r-PET market for tire textile filaments

CARBIOS enters the r-PET market for tire textile filaments

CARBIOS has signed a multi-year commercial agreement with Indorama Ventures, the world leader in polyester production. CARBIOS will supply recycled monomers that will be transformed into filaments by Indorama Ventures, intended for use in tire …

CARBIOS entre dans le marché du r-PET destiné aux filaments textiles pour pneumatiques

CARBIOS entre dans le marché du r-PET destiné aux filaments textiles pour pneumatiques

CARBIOS a signé un engagement commercial pluriannuel avec Indorama Ventures, leader mondial du polyester. CARBIOS fournira les monomères recyclés qui seront transformés en filaments par Indorama Ventures, et destinés au renfort de pneumatiques pour …

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells ( …

Sharecare introduces Condition Masterclass to support patient education and health literacy for chronic disease management

Sharecare introduces Condition Masterclass to support patient education and health literacy for chronic disease management

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced a new patient education destination that empowers …

Spirair Receives FDA Clearance for TurbAlign, a New Bioabsorbable Implant That Helps Keep Nasal Passages Open After Sinus Surgery

Spirair Receives FDA Clearance for TurbAlign, a New Bioabsorbable Implant That Helps Keep Nasal Passages Open After Sinus Surgery

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Spirair, Inc., an early-stage medical device company developing minimally invasive solutions to help otolaryngologists (ENTs) improve patient care, today announced that the U.S. Food and Drug …

VitalHub Announces Q2 2025 Conference Call Date

VitalHub Announces Q2 2025 Conference Call Date

TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it will release financial results for its second quarter 2025 ended June 30, 2025 after market close on August 7, 2025. The …

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today …

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company …

Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer

Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer

CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical …

Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025

Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025

Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025 Gdańsk, Poland - July 21, 2025 - Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in the development of innovative technology for cancer …

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical solution. Among the 17 patients who achieved complete …

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 …

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer’s Disease. Company receives expanded access …

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

WALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a …

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, …

Expanding Analyst Interest in ORYZON

Expanding Analyst Interest in ORYZON

MADRID and CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that Maxim LLC, a U.S.-based …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service